Opportunity Assessment: GLP-1 Receptor Agonists in the Egyptian Market
300,00$
Glucagon-like peptide-1 (GLP-1) receptor agonists are the fastest-growing therapeutic frontier in the Egyptian pharmaceutical market. The class expanded from roughly EGP 144 million in 2021 to approximately EGP 3.26 billion on a Moving Annual Total (MAT) basis to December 2025 — a four-year compound annual growth rate (CAGR) of about 118 percent. Opportunity score: 88 / 100
Description
PHARMACEUTICAL MARKET RESEARCH PROGRAM
Opportunity Assessment: GLP-1 Receptor Agonists in the Egyptian Market
Egypt’s Fastest-Growing Therapeutic Frontier
Data: Audited market sales, Egypt — MAT 2021–2025 · Product rankings MAT Dec 2025 · YTD Apr 2026
Opportunity score: 88 / 100
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists are the fastest-growing therapeutic frontier in the Egyptian pharmaceutical market. The class expanded from roughly EGP 144 million in 2021 to approximately EGP 3.26 billion on a Moving Annual Total (MAT) basis to December 2025 — a four-year compound annual growth rate (CAGR) of about 118 percent. Critically, and in sharp contrast to the mature core of the market, this growth is majority real volume rather than a currency artifact: unit demand is expanding rapidly, driven by Egypt’s exceptionally high burden of type 2 diabetes and obesity. The class is structured as an originator duopoly. MOUNJARO (tirzepatide) and OZEMPIC (semaglutide) together define the category, with MOUNJARO effectively doubling from a standing start and OZEMPIC growing units about 61 percent. Both brands are supply-constrained rather than demand-constrained — the binding limitation is manufacturing allocation and price accessibility, not patient appetite. The clinical evidence base is unusually strong: head-to-head randomized trials establish tirzepatide’s superiority over semaglutide on both glycemic control and weight reduction, and dedicated obesity trials demonstrate weight loss of 15 to 23 percent. Against a diabetic population of roughly 10.9 million adults and a far larger obese and overweight pool, current treated penetration is a small fraction of the eligible base, implying years of structural headroom. We assign an opportunity score of 88 out of 100 — the highest in the program to date — reflecting genuine volume growth, a durable clinical rationale, and vast unmet demand, tempered by supply constraint, affordability ceilings in a devaluing currency, and originator dominance that narrows the near-term entry window to biosimilar and access-led plays.
